RxDoctor Payments Data

Ilysa Bartol, PA

Physician Assistant · Gallatin, TNNPI 1447820097

Payments from drug & device makers

$2,392in general payments, 2019–2025

Across 107 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$801
  • Astellas Pharma US Inc$245
  • AbbVie$203
  • Pfizer$173
  • Sumitomo Pharma America, Inc.$169
  • Lundbeck LLC$155
  • plus $646 from 15 others

What the payments were for

  • Speaking & faculty fees$1255%
  • Food & beverage$2,20192%
  • Education$663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,392 in reported general payments places this provider in the 80th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$53,883
Medicare patients
193
Services billed
977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$122,823
JardianceEmpagliflozin120$120,303
MounjaroTirzepatide71$83,461
FarxigaDapagliflozin Propanediol45$39,319
LinzessLinaclotide42$28,564
XareltoRivaroxaban20$22,445
RexultiBrexpiprazole15$21,350
TrulicityDulaglutide21$20,742
EliquisApixaban26$19,575
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$19,054
Emgality PenGalcanezumab-Gnlm15$17,306
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$12,806
GemtesaVibegron16$11,071
VeozahFezolinetant16$8,111
MyrbetriqMirabegron12$7,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$801$122,82377 claims
Lilly USA, LLCMounjaro, Trulicity$88$104,20392 claims
AstraZenecaFarxiga, Breztri Aerosphere$62$52,12661 claims
AbbVieLinzess$203$28,56442 claims
Otsuka America Pharmaceutical, Inc.Rexulti$70$21,35015 claims
PfizerEliquis$173$19,57526 claims
Astellas Pharma US IncVeozah, Myrbetriq$245$16,05928 claims
Sumitomo Pharma America, Inc.Gemtesa$169$11,07116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Gallatin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →